PrairieGold Venture Partners

PrairieGold Venture Partners (PGVP) is an early-stage venture capital firm founded in 2003 and headquartered in Sioux Falls, South Dakota — one of the few established institutional VCs based in the Upper Midwest of the United States. The firm invests in life sciences, information technology, and energy and greentech companies, with a deliberate focus on Midwestern opportunities that allows it to take meaningful ownership positions with relatively modest capital commitments and play an active hands-on role in company strategy. Thematic priorities include early cancer detection, renewable energy, advanced surgical technologies, and differentiated agricultural and industrial biotechnology. PGVP operates multiple funds including PrairieGold Venture Capital Fund II LP and related Growth Capital Annex vehicles, and leads rounds at Series A and Series B. It typically provides follow-on capital across the life of its portfolio companies. The firm has disclosed approximately 14 portfolio investments; notable names include Virtual Incision (PGVP led its $30 million Series C alongside cultivate(MD) and InVivium Capital in September 2023), Agrivida (agricultural biotech and animal nutrition), Zea2 (bio-based commodity chemicals), and Lineagen (diagnostics). PGVP's team of 11 to 50 professionals combines venture capital, investment banking, legal, government, university, public relations, and industry operating experience. PGVP's regional positioning is both its thesis and its competitive advantage: by concentrating on the Midwest, the firm accesses exceptional science and engineering talent at earlier stages and lower valuations than coastal-based investors typically encounter. Its active management style and willingness to lead translates to genuine governance weight and the ability to help portfolio companies recruit executives, navigate regulatory pathways, and build strategic partnerships with regional industrial and academic anchors.